Edition:
United States

Synergy Pharmaceuticals Inc (SGYP.O)

SGYP.O on Nasdaq

4.00USD
22 Jul 2016
Change (% chg)

$0.08 (+2.04%)
Prev Close
$3.92
Open
$4.00
Day's High
$4.04
Day's Low
$3.92
Volume
1,894,507
Avg. Vol
3,821,323
52-wk High
$9.76
52-wk Low
$2.50

Latest Key Developments (Source: Significant Developments)

Synergy Pharmaceuticals Inc announces issuance of $200 mln of 7.50 pct convertible senior notes
Monday, 3 Nov 2014 04:01pm EST 

Synergy Pharmaceuticals Inc:Announced the closing of its previously announced private offering of $200 million aggregate principal amount of 7.50 pct Convertible Senior Notes due 2019.Notes are unsecured, senior obligations of Synergy and bear interest at a rate of 7.50 pct per year, payable semiannually in arrears on May 1 and Nov. 1 of each year, beginning on May 1, 2015.Notes will mature on Nov. 1, 2019, unless earlier purchased or converted.Intends to use the net proceeds from this offering primarily to fund the ongoing clinical development of plecanatide and any remaining proceeds will be used for working capital and other general corporate purposes.  Full Article

Synergy Pharmaceuticals Inc announces full exercise of over-allotment option
Thursday, 30 Oct 2014 06:00am EDT 

Synergy Pharmaceuticals Inc:Announces full exercise of the over-allotment option granted to the initial purchasers to purchase an additional $25 mln aggregate principal amount of 7.50 pct convertible senior notes due 2019.Says in connection with its previously announced $175 mln convertible senior note offering, bringing total gross proceeds from offering to $200 mln.Says offering (including the over-allotment option) is expected to close on or about Nov. 3, 2014, subject to customary closing conditions.  Full Article

Synergy Pharmaceuticals announces pricing of private offering of $175 mln of 7.50 pct convertible senior notes
Wednesday, 29 Oct 2014 08:48am EDT 

Synergy Pharmaceuticals Inc:Prices its private offering of $175 mln aggregate principal amount of 7.50 pct Convertible Senior Notes due 2019.Company also granted the initial purchasers of the notes an option to purchase, within a 13-day period beginning on and including the first date of the original issuance of the notes, up to an additional $25 mln principal amount of notes, solely to cover over-allotments.Offering is expected to close on or about Nov. 3.Intends to use the net proceeds from this offering primarily to fund the ongoing clinical development of plecanatide and any remaining proceeds will be used for working capital and other general corporate purposes.  Full Article

Synergy Pharmaceuticals Inc announces private offering of convertible senior notes
Tuesday, 28 Oct 2014 04:36pm EDT 

Synergy Pharmaceuticals Inc:Announced that it is offering to sell up to $150 million principal amount of its convertible senior notes due 2019 through a private offering.Expects to grant the initial purchasers of the notes an option to purchase, within a 13-day period beginning on and including the first date of the original issuance of the notes, up to an additional $22.5 mln principal amount of notes, solely to cover over-allotments.Offering is being made to qualified institutional buyers.  Full Article

Synergy Pharmaceuticals Inc to present additional positive phase 2b study results for Plecanatide in patients with irritable bowel syndrome with constipation
Tuesday, 7 Oct 2014 06:00am EDT 

Synergy Pharmaceuticals Inc:Presents additional positive data from a phase 2b study assessing plecanatide's efficacy and safety in patients with irritable bowel syndrome with constipation (IBS-C).Says data will be presented during plenary session at American College of Gastroenterology's 2014 Annual Scientific Meeting in Philadelphia, Pennsylvania on Oct. 20.Analysis indicated that study met its primary endpoint and important secondary endpoints, including Overall Responder endpoint for IBS-C.Says this was randomized, 12-week, double-blind, placebo-controlled, dose-ranging study to assess safety and efficacy of plecanatide in 424 adult patients with IBS-C.Study evaluated effects of 0.3, 1.0, 3.0 or 9.0 mg plecanatide or placebo administered orally, once-daily to adults meeting Rome III criteria for IBS-C.In addition, patients were required to meet criteria for IBS-C subtype, which is further characterized by stool pattern, such that ≥ 25 pct of defecations are hard or lump stools and ≤ 25 pct of defecations are loose or watery stools.Primary efficacy endpoint was the change from baseline in mean number of complete spontaneous bowel movements (CSBMs) the 12-week treatment period.Secondary endpoints included Abdominal Pain Intensity, Stool Consistency, Overall Responder (pct) and Abdominal Pain Responder.Says overall responder fulfilled both ≥ 30 pct reduction in worst abdominal pain and an increase of ≥ 1 CSBMs from baseline in same week for at least 50 pct of weeks.  Full Article

BRIEF-Synergy Pharma updates on FDA review clinical development program

* Provides update on ongoing FDA review Of Plecanatide CIC NDA and IBS-C clinical development program